Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience.
| Title: | Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience. |
|---|---|
| Authors: | Torres MB; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Department of Surgery, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, NJ, United States.; Leung CH; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Zoghbi M; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Lazcano R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Ingram D; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Wani K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Keung EZ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Zarzour MA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Scally CP; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Hunt KK; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Conley A; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Bishop AJ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Guadagnolo BA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Farooqi A; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Mitra D; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Yoder AK; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Nakazawa MS; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Araujo D; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Livingston A; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Ratan R; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Patel S; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Ravi V; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Lazar AJ; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Roland CL; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Somaiah N; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Nassif Haddad EF; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2025 Apr 30; Vol. 16, pp. 1567736. Date of Electronic Publication: 2025 Apr 30 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Lausanne : Frontiers Research Foundation] |
| MeSH Terms: | Liposarcoma*/drug therapy ; Liposarcoma*/mortality ; Liposarcoma*/immunology ; Liposarcoma*/pathology ; Immune Checkpoint Inhibitors*/therapeutic use ; Immune Checkpoint Inhibitors*/adverse effects; Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Adult ; Aged, 80 and over ; Treatment Outcome |
| Abstract: | Background: Dedifferentiated liposarcoma (DDLPS) is one of the most common types of soft tissue sarcoma (STS) characterized by liposarcomatous differentiation and a predilection for the retroperitoneum. Despite the growing number of histology-specific immune checkpoint blockade (ICB) trials in STS, it is still difficult to identify the radiographic objective response rate (ORR) for DDLPS in the real world setting. This study aimed to evaluate the ORR and survival of patients with DDLPS treated with ICB at a single center.; Methods: We conducted a retrospective study of 31 patients with pathologically confirmed DDLPS treated with ICB at MD Anderson Cancer Center between 2018 and 2023. Patient demographics, disease characteristics, treatment history, and response to ICB were analyzed. Immunohistochemical analysis was performed on tumor samples to assess immune-related markers.; Results: ORR by RECIST 1.1 was 3.2% (n=1/31). Among all patients (n=31), 6% achieved partial radiographic response, while 39% had stable disease, and 55% showed progressive disease. Median progression-free survival (PFS) was 3.5 (95%CI:1.9, 4.7) months, and overall survival (OS) after ICB initiation was 19.7 (95%CI: 8.8, not reached) months. Patients without prior systemic therapy demonstrated better OS (p=0.004). Immunohistochemistry revealed no relationship between pre- or post-ICB expression of CD8, CD20, CD21 and PDL-1 and response.; Conclusion: While the response to ICB in DDLPS remains limited, specific immune markers may influence treatment outcomes. CD20/21 post-ICB appear more important for prognosis. Further research is warranted to identify predictive factors for ICB efficacy in DDLPS.; (Copyright © 2025 Torres, Leung, Zoghbi, Lazcano, Ingram, Wani, Keung, Zarzour, Scally, Hunt, Conley, Bishop, Guadagnolo, Farooqi, Mitra, Yoder, Nakazawa, Araujo, Livingston, Ratan, Patel, Ravi, Lazar, Roland, Somaiah and Nassif Haddad.) |
| Competing Interests: | The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| References: | Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774); Eur J Surg Oncol. 2023 Jun;49(6):1053-1060. (PMID: 35151525); J Clin Oncol. 2007 May 1;25(13):1760-4. (PMID: 17470866); BMC Med. 2017 Jun 2;15(1):109. (PMID: 28571564); Clin Cancer Res. 2025 Feb 17;31(4):678-684. (PMID: 39699310); Surg Oncol Clin N Am. 2016 Oct;25(4):761-73. (PMID: 27591497); Pract Radiat Oncol. 2021 Sep-Oct;11(5):339-351. (PMID: 34326023); J Clin Oncol. 2016 Mar 10;34(8):786-93. (PMID: 26371143); Nat Cancer. 2024 Apr;5(4):625-641. (PMID: 38351182); Ann Oncol. 2017 Dec 01;28(12):2994-2999. (PMID: 29045512); Ann Oncol. 2012 Jun;23(6):1601-7. (PMID: 22039081); Lancet Oncol. 2017 Nov;18(11):1493-1501. (PMID: 28988646); Cancers (Basel). 2023 Apr 13;15(8):. (PMID: 37190214); Lancet Oncol. 2018 Mar;19(3):416-426. (PMID: 29370992); Front Immunol. 2021 Dec 03;12:775761. (PMID: 34925348); Science. 2020 Jan 31;367(6477):. (PMID: 32001626); Nature. 2020 Jan;577(7791):556-560. (PMID: 31942077); Cancer Med. 2023 Feb;12(4):4282-4293. (PMID: 36151848); J Hematol Oncol. 2020 May 19;13(1):55. (PMID: 32430039); Lancet. 2024 Nov 23;404(10467):2053-2064. (PMID: 39547252); Ann Oncol. 2019 Jul 1;30(7):1143-1153. (PMID: 31081028); Sci Rep. 2017 Sep 19;7(1):11836. (PMID: 28928422); Mod Pathol. 2019 Dec;32(12):1772-1785. (PMID: 31263176); Cancer. 2022 Aug 1;128(15):2932-2938. (PMID: 35561319); Biomark Res. 2023 Aug 23;11(1):75. (PMID: 37612756); J Clin Oncol. 2011 Jun 20;29(18):2528-33. (PMID: 21606430); Lancet Oncol. 2022 Sep;23(9):1156-1166. (PMID: 35934010); Curr Oncol. 2023 Feb 09;30(2):2144-2158. (PMID: 36826126); Lancet Oncol. 2020 Oct;21(10):1366-1377. (PMID: 32941794); Cancer. 2021 Mar 15;127(6):894-904. (PMID: 33231866); J Natl Compr Canc Netw. 2022 Jul;20(7):834-844. (PMID: 35830892); Lancet Oncol. 2017 Mar;18(3):e143-e152. (PMID: 28271869); Int J Mol Sci. 2021 Jul 13;22(14):. (PMID: 34299136); Curr Opin Oncol. 2011 Jul;23(4):373-8. (PMID: 21552124); Front Immunol. 2024 Jun 25;15:1378398. (PMID: 38983859); Lancet. 2016 Apr 16;387(10028):1629-37. (PMID: 26874885); Int Immunopharmacol. 2018 Sep;62:29-39. (PMID: 29990692); J Clin Oncol. 2005 Jan 20;23(3):576-84. (PMID: 15659504); Radiology. 2009 May;251(2):447-56. (PMID: 19261927); Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e432234. (PMID: 38781557); Ann Oncol. 2021 Nov;32(11):1348-1365. (PMID: 34303806); CA Cancer J Clin. 2020 May;70(3):200-229. (PMID: 32275330); Cancer Cell Int. 2020 Dec 2;20(1):577. (PMID: 33292275); Eur J Cancer. 2015 Jan;51(2):202-9. (PMID: 25499439); Lancet Oncol. 2017 Oct;18(10):1397-1410. (PMID: 28882536) |
| Grant Information: | K12 CA088084 United States CA NCI NIH HHS; P50 CA272170 United States CA NCI NIH HHS |
| Contributed Indexing: | Keywords: Anti-PD1; dedifferentiated liposarcoma; immune-checkpoint inhibitors; immunotherapy; sarcoma; survival |
| Substance Nomenclature: | 0 (Immune Checkpoint Inhibitors) |
| Entry Date(s): | Date Created: 20250515 Date Completed: 20250515 Latest Revision: 20260408 |
| Update Code: | 20260408 |
| PubMed Central ID: | PMC12075363 |
| DOI: | 10.3389/fimmu.2025.1567736 |
| PMID: | 40370451 |
| Database: | MEDLINE |
Journal Article